Rimonabant: marketing authorization suspended... at last: withdrawal. Half-measures.
Marketing authorization was granted for rimonabant on the basis of shaky data and despite poorly documented dangers. It took the EMEA 2 years to take action, by advising practitioners not to prescribe this drug.